Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 5/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161582 | 0.97 | CRBN (0.37) | CRBNDDB1MEN1KMT2AACACB | |
| SCHEMBL26101474 | 0.85 | ACACB (0.47) | CRBNDDB1MEN1KMT2AACACB | |
| SCHEMBL26509089 | 0.85 | MEN1 (0.46) | CRBNDDB1MEN1KMT2AACACB | |
| SCHEMBL26099471 | 0.85 | MEN1 (0.52) | CRBNDDB1MEN1KMT2APDK1 | |
| SCHEMBL31161731 | 0.82 | CRBN (0.38) | CRBNDDB1KMT2AENPP2ATXN2 | |
| SCHEMBL31161368 | 0.81 | MEN1 (0.39) | CRBNDDB1MEN1KMT2APDK1 | |
| Trifluoroacetic Acid SCHEMBL31161661 | 0.80 | DDR1 (0.36) | CRBNKMT2AACACBENPP2ATXN2 | |
| SCHEMBL31161762 | 0.80 | ACACB (0.36) | CRBNDDB1MEN1KMT2AACACB | |
| SCHEMBL23121362 | 0.79 | KMT2A (0.44) | CRBNDDB1MEN1KMT2APDK1 | |
| SCHEMBL26099001 | 0.79 | CNR2 (0.43) | CRBNDDB1MEN1KMT2APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | CRBN 91/4885DDB1 3238/4885MEN1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.